Key result
Dual anti-HER2 therapy is linked to Takotsubo cardiomyopathy in metastatic breast cancer.
Case Report (n=1)
This represents the first reported case of Takotsubo cardiomyopathy associated with pertuzumab plus trastuzumab combination therapy.
Answers are grounded in this paper and cite their sources.
May warrant vigilance for Takotsubo cardiomyopathy on dual anti-HER2 therapy; first case leaves open causality and incidence.
Human epidermal growth factor receptor 2 (HER2)-targeted antibodies, including pertuzumab and trastuzumab, improve overall survival and progression-free survival among women with HER2-positive metastatic breast cancer, but grade ≥3 cardiotoxicity occurs in approximately 8% of cases. Here we report a case of Takotsubo cardiomyopathy associated with the use of dual anti-HER2 therapy in a 63-year-old woman who presented to the emergency department with an 8- to 10-hour history of progressive dyspnea after completing her third cycle of pertuzumab plus trastuzumab in addition to nab-paclitaxel chemotherapy. To our knowledge, this patient represents the first reported case of Takotsubo cardiomyopathy associated with pertuzumab plus trastuzumab combination therapy in the literature.
No takes yet. Share an insight, caveat, or question.
Lees et al. (2018) conducted a case report in HER2-positive metastatic breast cancer (n=1). Pertuzumab plus trastuzumab and nab-paclitaxel was evaluated on Takotsubo cardiomyopathy. Dual anti-HER2 therapy with pertuzumab and trastuzumab was associated with the development of Takotsubo cardiomyopathy in a 63-year-old woman with metastatic breast cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: